. ELTP_ Elite Pharmaceuticals Announces Positive Top-Line Results From A Pivotal Phase 3 Study For Abuse-Deterrent Opioid ELI-200 . Near term Goals : ELI 200 submission in 2015 & approval in 2016 Continuing manufacturing facility´s expansion, equipment upgrade and staffing
- Loxapine & Dantrolene launch - Filling two more opioid products in 2016 - ELI 200 product launch with marketing partner
Revenue growth from niche generics and first ADF product
Profitability Base generic business profitable in 2016 R&D costs supported with ELI 200 in 2017
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.